PlainRecalls
FDA Drug Moderate Class II Ongoing

Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 160 mg/12.5 mg tablets, USP 90-count bottle, Rx Only, Rx Only, Manufactured by: Arrow Pharma (Malta) Ltd. India, Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054. NDC 0591-2316-19.

Reported: August 1, 2018 Initiated: July 16, 2018 #D-0982-2018

Product Description

Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 160 mg/12.5 mg tablets, USP 90-count bottle, Rx Only, Rx Only, Manufactured by: Arrow Pharma (Malta) Ltd. India, Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054. NDC 0591-2316-19.

Reason for Recall

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
195,234 bottles
Distribution
Product was distributed throughout the United States, including Hawaii and Puerto Rico
Location
North Wales, PA

Frequently Asked Questions

What product was recalled?
Valsartan and Hydrochlorothiazide (HCTZ) Tablets, USP 160 mg/12.5 mg tablets, USP 90-count bottle, Rx Only, Rx Only, Manufactured by: Arrow Pharma (Malta) Ltd. India, Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054. NDC 0591-2316-19.. Recalled by Teva Pharmaceuticals USA. Units affected: 195,234 bottles.
Why was this product recalled?
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 1, 2018. Severity: Moderate. Recall number: D-0982-2018.